Kyntra Bio (KYNB) Operating Income (2014 - 2026)
Kyntra Bio (KYNB) posted Operating Income of -$13.8 million for Q1 2026, down 2.26% sequentially from -$13.5 million in Q4 2025, and up 7.39% YoY from -$12.9 million in Q1 2025.
Kyntra Bio (KYNB) Operating Income (2014 - 2026) Analysis & Trends
Kyntra Bio has reported Operating Income for 13 years, with the latest figure at -$13.8 million in Q1 2026.
- Quarterly Operating Income rose 7.39% year-over-year to -$13.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$44.8 million (up 61.44% YoY) and the FY2025 annual result came in at -$45.9 million, up 69.49% from the prior year.
- Operating Income fell to -$13.8 million in Q1 2026 per KYNB's latest filing, from -$13.5 million in the prior quarter.
- Over five years, Operating Income peaked at -$5.4 million in Q3 2025 and troughed at -$95.1 million in Q4 2023.
- A 5-year average of -$49.1 million and a median of -$49.2 million in 2024 frame the typical range for Operating Income.
- The sharpest annual moves came in 2022 and 2024: Operating Income tumbled 283.73% in 2022, then jumped 92.5% in 2024.
- Over 5 years, Operating Income stood at -$66.2 million in 2022, then slumped by 43.76% to -$95.1 million in 2023, then surged by 92.5% to -$7.1 million in 2024, then tumbled by 89.43% to -$13.5 million in 2025, then fell by 2.26% to -$13.8 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$13.8 million, -$13.5 million, and -$5.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | Kyntra Bio | 30.42 Mn | 30.42 Mn | 1.47 Mn | -17.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.57 Mn |
| Mar 31, 2026 | -13.82 Mn |
| Dec 31, 2025 | -13.51 Mn |
| Sep 30, 2025 | -5.41 Mn |
| Jun 30, 2025 | -12.05 Mn |
| Mar 31, 2025 | -14.92 Mn |
| Dec 31, 2024 | -7.13 Mn |
| Sep 30, 2024 | -47.69 Mn |
| Jun 30, 2024 | -46.41 Mn |
| Mar 31, 2024 | -49.18 Mn |
| Dec 31, 2023 | -95.10 Mn |
| Sep 30, 2023 | -63.48 Mn |
| Jun 30, 2023 | -88.05 Mn |
| Mar 31, 2023 | -76.09 Mn |
| Dec 31, 2022 | -66.15 Mn |
| Sep 30, 2022 | -93.66 Mn |
| Jun 30, 2022 | -78.22 Mn |
| Mar 31, 2022 | -62.99 Mn |
| Dec 31, 2021 | -135.24 Mn |
| Sep 30, 2021 | 50.97 Mn |